2-(4-(4-Methoxybenzoyl)piperidin-1-YL)acetic acid → 2-(4-(4-Methoxybenzoyl)piperidin-1-yl)-N-((4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)methyl)acetamide

Participants

Reaction Steps

The title compound (100 mg) was prepared following the general procedure of Example 1 from 2-(4-(4-methoxybenzoyl)piperidin-1-yl)acetic acid (265 mg, 0.67 mmol, 70% purity) and 2-(aminomethyl)-5,6,7,8-tetrahydroquinazolin-4(3H)-one (120 mg, 0.67 mmol). 1H NMR (400 MHz, CDC3) δ 10.91 (br. s., 1H), 7.91 (br. s., 1H), 7.82-7.89 (m, 2H), 6.85-6.91 (m, J=8.6 Hz, 2H), 4.29 (d, J=6.1 Hz, 2H), 3.81 (s, 3H), 3.17 (d, J=6.6 Hz, 1H), 3.07 (br. s., 2H), 2.90 (br. s., 2H), 2.52 (t, J=6.1 Hz, 2H), 2.42 (t, J=6.1 Hz, 4H), 1.80 (br. s., 4H), 1.48-1.77 (m, 4H). HRMS calculated for C24H30N4O4 439.2345. found (ESI, [M+H]+), 439.2352. Retention time=2.84 min.

Provenance & Evidence